Novo Nordisk launches long acting basal insulin
Bangalore, May 13 (UNI) Novo Nordisk today launched Levemir, a novel predictable basal insulin analogue with a unique mechanism of prolonging action for people suffering from type 1 and type 2 diabetes in India.
Levemir provided predictable and cosnsitent control of blood glucose levels. This would enable blood glucose levels maintained within a very narrow range, especially during the night. It provided an opportunity for people with diabetes to achieve consistent dosing which facilitated optimal glycaemic control, the company said in a release here today.
Speaking about the launch, Melvin Oscar D'Souza, Managing Director of Novo Nordisk India said the company was the first in India to have short and long acting insulin analogue for adults and children.
UNI VK RKN1238